Tag: Ophthalmology and Vision
Xinxin Zhang Named 2017 Koch Kellan Scholar
PORTLAND, Ore. /ScoopCloud/ -- Paragon BioTeck, Inc., an ophthalmic pharmaceutical and device company, announced today that Xinxin Zhang has been named its 2017 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology.
Ruling Affirms Patent Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formulation
PORTLAND, Ore., /ScoopCloud/ -- Paragon BioTeck, Inc. announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.
Hasenin Al-khersan Named 2016 Koch Kellan Scholar
PORTLAND, Ore., April 18, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., announced today that Hasenin Al-khersan has been named its 2016 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology.
Paragon BioTeck to Exhibit at American Academy of Ophthalmology Annual Meeting in Chicago
PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 - 21.
Novel Protein May Hold Promise for Enhancing Artificial Tear Formulations
PLYMOUTH, Minn., Oct. 14, 2014 (SEND2PRESS NEWSWIRE) -- SilkTears, LLC, a privately held, research-based and product-driven biotechnology company, announced today that advances in protein-based excipient technology may allow for the development of artificial tear products that will more closely represent certain characteristics of the natural makeup of the tear film, and may help the significant population of patients suffering from dry eye syndrome.